Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COXFA4 | O00483 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16694306 | 0.92 | HIF1A (0.62) | COXFA4HIF1AEPAS1HSP90AA1RECQL | |
| SCHEMBL16865491 | 0.85 | COXFA4 (0.59) | COXFA4HIF1AEPAS1HSP90AA1 | |
| SCHEMBL16865564 | 0.82 | HIF1A (0.56) | COXFA4HIF1AEPAS1NPC1HSD17B10 | |
| SCHEMBL8885308 | 0.78 | MAPT (0.61) | COXFA4HIF1AEPAS1NPC1SMN1; SMN2 | |
| SCHEMBL8883383 | 0.77 | COXFA4 (0.52) | COXFA4HIF1AEPAS1NPC1SMN1; SMN2 | |
| SCHEMBL8882813 | 0.76 | MEN1 (0.52) | COXFA4HIF1ANPC1RAB9A | |
| SCHEMBL14098880 | 0.76 | COXFA4 (0.61) | COXFA4HIF1AEPAS1HSP90AA1 | |
| SCHEMBL16694415 | 0.76 | HIF1A (0.66) | COXFA4HIF1AEPAS1NPC1HSP90AA1 | |
| SCHEMBL16865512 | 0.76 | HIF1A (0.57) | COXFA4HIF1AEPAS1HSP90AA1 | |
| SCHEMBL16865511 | 0.76 | HIF1A (0.57) | COXFA4HIF1AEPAS1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HIF1AN | COXFA4 3510/4885HIF1A 5/4885EPAS1 55/4885 |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HSP90AB2P | COXFA4 3670/4885HIF1A 6/4885EPAS1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.